Tumour and microparticle tissue factor expression and cancer thrombosis

Thrombosis Research

Volumn 131, Issue 2, 2013, Pages 109-115

  Date, Kathryn ^a   Hall, Jessica ^a   Greenman, John ^a   Maraveyas, Anthony ^b   Madden, Leigh A ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

procoagulant activity; tissue factor; tumour microparticles; Venous thromboembolism

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LENALIDOMIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PLATINUM DERIVATIVE; SPHINGOMYELIN; TAXANE DERIVATIVE; TENIPOSIDE; THALIDOMIDE; THROMBOPLASTIN; VINCRISTINE;

APOPTOSIS; BLOOD CLOTTING; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL DAMAGE; CELL VACUOLE; CHEMOSENSITIVITY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FLOW CYTOMETRY; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE MICROPARTICLE; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR THROMBUS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; CELL-DERIVED MICROPARTICLES; HUMANS; NEOPLASMS; THROMBOPLASTIN; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84872299110     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.11.013     Document Type: Review

References (119)

1. A. Falanga, and L. Russo Epidemiology, risk and outcomes of venous thromboembolism in cancer Hamostaseologie 32 2 2012 115 125
2. J.L. Yu, L. May, V. Lhotak, S. Shahrzad, S. Shirasawa, and J.I. Weitz Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis Blood 105 4 2005 1734 1741
3. A.A. Khorana, C.W. Francis, E. Culakova, R.I. Fisher, N.M. Kuderer, and G.H. Lyman Thromboembolism in Hospitalized Neutropenic Cancer Patients J Clin Oncol 24 3 2006 484 490
4. T.J. Semrad, R. O'Donnell, T. Wun, H. Chew, D. Harvey, and H. Zhou Epidemiology of venous thromboembolism in 9489 patients with malignant glioma J Neurosurg 106 4 2007 601 608
5. H.K. Chew, T. Wun, D.J. Harvey, H. Zhou, and R.H. White Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients J Clin Oncol 25 1 2007 70 76
6. H.K. Chew, A.M. Davies, T. Wun, D. Harvey, H. Zhou, and R.H. White The incidence of venous thromboembolism among patients with primary lung cancer J Thromb Haemost 6 4 2008 601 608
7. C.P.W. Klerk, S.M. Smorenburg, H.-M. Otten, A.W.A. Lensing, M.H. Prins, and F. Piovella The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy J Clin Oncol 23 10 2005 2130 2135
8. A. Lazo-Langner, G.D. Goss, J.N. Spaans, and M.A. Rodger The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials J Thromb Haemost 5 4 2007 729 737
9. R. Sud, and A.A. Khorana Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model Thromb Res 123 Suppl. 4 2009 S18 S21
10. G.J. Caine, P.S. Stonelake, G.Y.H. Lip, and S.T. Kehoe The hypercoagulable state of malignancy: Pathogenesis and current debate Neoplasia 4 6 2002 465 473
11. A.A. Khorana, C.W. Francis, E. Culakova, N.M. Kuderer, and G.H. Lyman Frequency, risk factors, and trends for venous thromboembolism among hospitalised cancer patients Cancer 110 10 2007 2339 2346
12. A. Maraveyas, J. Waters, R. Roy, D. Fyfe, D. Propper, and F. Lofts Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer Eur J Cancer 48 9 2012 1283 1292
13. A. Alcalay, T. Wun, V. Khatri, H.K. Chew, D. Harvey, and H. Zhou Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival J Clin Oncol 24 7 2006 1112 1118
14. H.K. Chew, T. Wun, D. Harvey, H. Zhou, and R.H. White Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 166 4 2006 458 464
15. M. Mandalà, M. Reni, S. Cascinu, S. Barni, I. Floriani, and S. Cereda Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients Ann Oncol 18 10 2007 1660 1665
16. T. Wun, and R.H. White Epidemiology of cancer-related venous thromboembolism Best Pract Res Clin Haematol 22 1 2009 9 23
17. A. Falanga, and M. Marchetti Anticancer treatment and thrombosis Thromb Res 129 3 2012 353 359
18. A. Maraveyas, and M. Johnson Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Br J Cancer 100 12 2009 1837 1841
19. C.A. Rodrigues, R. Ferrarotto, R.K. Filho, Y.A.S. Novis, and P.M.G. Hoff Venous thromboembolism and cancer: a systematic review J Thromb Thrombolysis 30 1 2010 67 78
20. B. Furie, and B.C. Furie Cancer-associated thrombosis Blood Cells Mol Dis 36 2 2006 177 181
21. B. Kocatürk, and H.H. Versteeg Tissue factor isoforms in cancer and coagulation: may the best isoform win Thromb Res 129 Suppl. 1 2012 S69 S75
22. F. Schaffner, N. Yokota, and W. Ruf Tissue factor proangiogenic signalling in cancer progression Thromb Res 129 Suppl. 1 2012 S127 S131
23. H. Echrish, L.A. Madden, J. Greenman, and A. Maraveyas (PO-84) Expression of tissue factor (TF) and growth factor receptors on pancreatic cell lines: correlation with TF activity and cell invasion Thromb Res 125 Suppl. 2 2010 S188 S189
24. J. Welsh, J.D. Smith, K.R. Yates, J. Greenman, A. Maraveyas, and L.A. Madden Tissue factor expression determines tumour cell coagulation kinetics Int J Lab Hematol 34 4 2012 396 402
25. L.V.M. Rao Tissue factor as a tumor procoagulant Cancer Metastasis Rev 11 3 1992 249 266
26. A.A. Khorana, S.A. Ahrendt, C.K. Ryan, C.W. Francis, R.H. Hruban, and Y.C. Hu Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer Clin Cancer Res 13 10 2007 2870 2875
27. A.K. Kakkar, N. DeRuvo, V. Chinswangwatanakul, S. Tebbutt, and R.C.N. Williamson Extrinsic-pathway activation in cancer with high factor Vlla and tissue factor Lancet 346 8981 1995 1004 1005
28. N. Nitori, Y. Ino, Y. Nakanishi, T. Yamada, K. Honda, and K. Yanagihara Prognostic Significance of Tissue Factor in Pancreatic Ductal Adenocarcinoma Clin Cancer Res 11 7 2005 2531 2539
29. A.P. Owens, and N. Mackman Microparticles in Hemostasis and Thrombosis Circ Res 108 10 2011 1284 1297
30. T. Ueno, M. Toi, M. Koike, S. Nakamura, and T. Tominaga Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration Br J Cancer 83 2 2000 164 170
31. L.Y. Han, C.N. Landen, A.A. Kamat, A. Lopez, D.P. Bender, and P. Mueller Preoperative Serum Tissue Factor Levels Are an Independent Prognostic Factor in Patients With Ovarian Carcinoma J Clin Oncol 24 5 2006 755 761
32. C.M. Boulanger, N. Amabile, and A. Tedgui Circulating Microparticles Hypertension 48 2 2006 180 186
33. A. Falanga, C.J. Tartari, and M. Marchetti Microparticles in tumour progression Thromb Res 129 Suppl. 1 2012 S132 S136
34. S.A. Smith The cell-based model of coagulation J Vet Emerg Crit Care (San Antonio) 19 1 2009 3 10
35. P. Bucciarelli, I. Martinelli, A. Artoni, S.M. Passamonti, E. Previtali, and G. Merati Circulating microparticles and risk of venous thromboembolism Thromb Res 129 5 2012 591 597
36. J.M. Freyssinet Cellular microparticles: what are they bad or good for? J Thromb Haemost 1 7 2003 1655 1662
37. J. Simak, and M.P. Gelderman Cell Membrane Microparticles in Blood and Blood Products: Potentially Pathogenic Agents and Diagnostic Markers Transfus Med Rev 20 1 2006 1 26
38. O. Morel, L. Jesel, J.-M. Freyssinet, and F. Toti Cellular Mechanisms Underlying the Formation of Circulating Microparticles Arterioscler Thromb Vasc Biol 31 1 2011 15 26
39. D. Castellana, F. Toti, and J.-M. Freyssinet Membrane microvesicles: Macromessengers in cancer disease and progression Thromb Res 125 Suppl. 2 2010 S84 S88
40. J. Baran, M. Baj-Krzyworzeka, K. Weglarczyk, R. Szatanek, M. Zembala, and J. Barbasz Circulating tumour-derived microvesicles in plasma of gastric cancer patients Cancer Immunol Immunother 59 6 2010 841 850
41. J. Thaler, C. Ay, H. Weinstabl, D. Dunkler, R. Simanek, and R. Vormittag Circulating procoagulant microparticles in cancer patients Ann Hematol 90 4 2011 447 453
42. F. van Doormaal, A. Kleinjan, R.J. Berckmans, N. Mackman, D. Manly, and P.W. Kamphuisen Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study Thromb Haemost 108 1 2012 160 165
43. S. Zahra, J.A.M. Anderson, D. Stirling, and C.A. Ludlam Microparticles, malignancy and thrombosis Br J Haematol 152 6 2011 688 700
44. K. Aupeix, B. Hugel, T. Martin, P. Bischoff, H. Lill, and J.L. Pasquali The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection J Clin Invest 99 7 1997 1546 1554
45. M. Baj-Krzyworzeka, R. Szatanek, K. Wȩglarczyk, J. Baran, B. Urbanowicz, and P. Brański Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes Cancer Immunol Immunother 55 7 2006 808 818
46. D. Castellana, C. Kunzelmann, and J.M. Freyssinet Pathophysiologic significance of procoagulant microvesicles in cancer disease and progression Hamostaseologie 29 1 2009 51 57
47. M.E.T. Tesselaar, F.P.H.T.M. Romijn, I.K. Van Der Linden, F.A. Prins, R.M. Bertina, and S. Osanto Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5 3 2007 520 527
48. J.I. Zwicker, H.A. Liebman, D. Neuberg, R. Lacroix, K.A. Bauer, and B.C. Furie Tumor-Derived Tissue Factor-Bearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy Clin Cancer Res 15 22 2009 6830 6840
49. V. Dolo, E. Adobati, S. Canevari, M.A. Picone, and M.L. Vittorelli Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens Clin Exp Metastasis 13 4 1995 277 286
50. C. Gercel-Taylor, S. Atay, R.H. Tullis, M. Kesimer, and D.D. Taylor Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients Anal Biochem 428 1 2012 44 53
51. M. Davila, A. Amirkhosravi, E. Coll, H. Desai, L. Robles, and J. Colon Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation J Thromb Haemost 6 9 2008 1517 1524
52. H.H.J. Echrish, L. Madden, J. Greenman, K. Wedgwood, D. Dasgupta, and A. Maraveyas (P-TU-402) Pro-thrombotic indices and invasive-angiogenic properties of blood from pancreatic cancer (PC) patients improve after cancer resection: a prospective controlled study J Thromb Haemost 9 s2 2011 434 435
53. H.F. Dvorak, S.C. Quay, N.S. Orenstein, A.M. Dvorak, P. Hahn, and A.M. Bitzer Tumour shedding and coagulation Science 212 4497 1981 923 924
54. J.L. Yu, and J.W. Rak Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells J Thromb Haemost 2 11 2004 2065 2067
55. V.Y. Bogdanov, V. Balasubramanian, J. Hathcock, O. Vele, M. Lieb, and Y. Nemerson Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein Nat Med 9 4 2003 458 462
56. P. Censarek, A. Bobbe, M. Grandoch, K. Schrör, and A.-A. Weber Alternatively spliced human tissue factor (asHTF) is not pro-coagulant Thromb Haemost 97 1 2007 11 14
57. E. Bastida, A. Ordinas, G. Escolar, and G. Jamieson Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis Blood 64 1 1984 177 184
58. K.R. Yates, J. Welsh, H.H. Echrish, J. Greenman, A. Maraveyas, and L.A. Madden Pancreatic cancer cell and microparticle procoagulant surface characterization: involvement of membrane-expressed tissue factor, phosphatidylserine and phosphatidylethanolamine Blood Coagul Fibrinolysis 22 8 2011 680 687
59. E. Campello, L. Spiezia, C.M. Radu, C. Bulato, M. Castelli, and S. Gavasso Endothelial, platelet and tissue-factor bearing microparticles in cancer patients with and without venous thromboembolism Thromb Res 127 2011 473 477
60. J.J.A. Auwerda, Y. Yuana, S. Osanto, M.P.M. de Maat, P. Sonneveld, and R.M. Bertina Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma Thromb Haemost 105 1 2011 14 20
61. S. Falati, Q. Liu, P. Gross, G. Merrill-Skoloff, J. Chou, and E. Vandendries Accumulation of Tissue Factor into Developing Thrombi In Vivo Is Dependent upon Microparticle P-Selectin Glycoprotein Ligand 1 and Platelet P-Selectin J Exp Med 197 11 2003 1585 1598
62. G.M. Thomas, L. Panicot-Dubois, R. Lacroix, F. Dignat-George, D. Lombardo, and C. Dubois Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo J Exp Med 206 9 2009 1913 1927
63. A.A. Khorana, C.W. Francis, K.E. Menzies, J.G. Wang, O. Hyrien, and J. Hathcock Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer J Thromb Haemost 6 11 2008 1983 1985
64. D.A. Manly, J. Wang, S.L. Glover, R. Kasthuri, H.A. Liebman, and N.S. Key Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism Thromb Res 125 6 2010 511 512
65. J.-G. Wang, J.E. Geddings, M.M. Aleman, J.C. Cardenas, P. Chantrathammachart, and J.C. Williams Tumour-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer Blood 119 23 2012 5543 5552
66. M.E. Tesselaar, F.P. Romijn, I.K. van der Linden, R.M. Bertina, and S. Osanto Microparticle-associated tissue factor activity in cancer patients with and without thrombosis J Thromb Haemost 7 8 2009 1421 1423
67. J. Thaler, C. Ay, N. Mackman, R.M. Bertina, A. Kaider, and C. Marosi Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients J Thromb Haemost 10 2012 1363 1370
68. N.S. Key Analysis of tissue factor positive microparticles Thromb Res 125 2010 S42 S45
69. Y. Yuana, R.M. Bertina, and S. Osanto Pre-analytical and analytical issues in the analysis of blood microparticles Thromb Haemost 105 2011 396 408
70. H.-M.M.B. Otten, J. Mathijssen, H. ten Cate, M. Soesan, M. Inghels, and D.J. Richel Symptomatic Venous Thromboembolism in Cancer Patients Treated With Chemotherapy: An Underestimated Phenomenon Arch Intern Med 164 2 2004 190 194
71. S. Tateo, L. Mereu, S. Salamano, C. Klersy, M. Barone, and A.C. Spyropoulos Ovarian cancer and venous thromboembolic risk Gynecol Oncol 99 1 2005 119 125
72. A.A. Brandes, E. Scelzi, G. Salmistraro, M. Ermani, C. Carollo, and F. Berti Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study Eur J Cancer 33 10 1997 1592 1596
73. H.F.P. Hillen Thrombosis in cancer patients Ann Oncol 11 Suppl. 3 2000 273 276
74. M.N. Levine, M. Gent, J. Hirsch, A. Arnold, M.D. Goodyear, and W. Hryniuk The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer N Engl J Med 318 1988 404 407
75. M. Mandalà, S. Barni, M. Prins, R. Labianca, C. Tondini, and L. Russo Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial Ann Oncol 21 4 2010 871 876
76. S.V. Rajkumar, S. Jacobus, N.S. Callander, R. Fonseca, D.H. Vesole, and M.E. Williams Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised control trial Lancet Oncol 11 1 2010 29 37
77. M. Zangari, E. Anaissie, B. Barlogie, A. Badros, R. Desikan, and A.V. Gopal Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy Blood 98 5 2001 1614 1615
78. M. Zangari, B. Barlogie, E. Anaissie, F. Saghafifar, P. Eddlemon, and J. Jacobson Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation Br J Haematol 126 5 2004 715 721
79. T.C. Haddad, and E.W. Greeno Chemotherapy-induced thrombosis Thromb Res 118 5 2006 555 568
80. T. Sousou, and A.A. Khorana New Insights Into Cancer-Associated Thrombosis Arterioscler Thromb Vasc Biol 29 3 2009 316 320
81. J. Bhosle, and G. Hall Principles of cancer treatment by chemotherapy Surgery (Oxford) 27 4 2009 173 177
82. N. Starling, S. Rao, D. Cunningham, T. Iveson, M. Nicolson, and F. Coxon Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group J Clin Oncol 27 23 2009 3786 3793
83. J.F. San Miguel, M. Dimopoulos, D.M. Weber, M. Olesnyckyj, Z. Yu, and J.B. Zeldis Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM-009/010 subanalysis) ASH Annu Meet Abstr 110 2007 A2712 [abstr.]
84. E.W. Greeno, R.R. Bach, and C.F. Moldow Apoptosis is associated with increased cell surface tissue factor procoagulant activity Lab Invest 75 2 1996 281 289
85. L. Ma, G. Francia, A. Viloria-Petit, D.J. Hicklin, J. du Manoir, and J. Rak In vitro Procoagulant Activity Induced in Endothelial Cells by Chemotherapy and Antiangiogenic Drug Combinations: Modulation by Lower-Dose Chemotherapy Cancer Res 65 12 2005 5365 5373
86. L.L. Swystun, L.Y.Y. Shin, S. Beaudin, and P.C. Liaw Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes J Thromb Haemost 7 4 2009 619 626
87. C.F. Reich III, and D.S. Pisetsky The content of DNA and RNA in microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis Exp Cell Res 315 5 2009 760 768
88. P.F. Neuenschwander, E. Bianco-Fisher, A.R. Rezaie, and J.H. Morrissey Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine Biochemistry 34 43 1995 13988 13993
89. J.C. Boles, J.C. Williams, R.M. Hollingsworth, J.-G. Wang, S.L. Glover, and A.P. Owens Iii Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity Thromb Res 129 2 2012 197 203
90. A. Maraveyas, C. Ettelaie, H. Echrish, C. Li, E. Gardiner, and J. Greenman Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion Blood Coagul Fibrinolysis 21 5 2010 452 458
91. S.D. Mukherjee, L.L. Swystun, N. Mackman, J.G. Wang, G. Pond, and M.N. Levine Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients Pathophysiol Haemost Thromb 37 2-4 2010 88 97
92. L.L. Swystun, S. Mukherjee, and P.C. Liaw Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus J Thromb Haemost 9 11 2011 2313 2321
93. S.C. Howard, D.P. Jones, and C.H. Pui The tumor lysis syndrome N Engl J Med 364 19 2011 1844 1854
94. G. Cesarman-Maus, E. Braggio, H. Maldonado, and R. Fonseca Absence of tissue factor expression by neoplastic cells in multiple myeloma Leukemia 26 7 2012 1671 1674
95. S.V. Rajkumar, S. Hayman, M.A. Gertz, A. Dispenzieri, M.Q. Lacy, and P.R. Greipp Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 21 2002 4319 4323
96. M. Cavo, E. Zamagni, P. Tosi, P. Tacchetti, C. Cellini, and D. Cangini Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 106 1 2005 35 39
97. S.V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P.R. Griepp Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group J Clin Oncol 24 3 2006 431 436
98. V.H. Jimenez-Zepeda, and V.J. Domínguez-Martínez Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? Eur J Haematol 77 3 2006 239 244
99. S.V. Rajkumar, L. Rosiñol, M. Hussein, J. Catalano, W. Jedrzejczak, and L. Lucy Multicentre, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma J Clin Oncol 26 13 2008 2171 2177
100. A. Palumbo, A. Bertola, P. Falco, R. Rosato, F. Cavallo, and L. Giaccone Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma Hematol J 5 4 2004 318 324
101. A. Anagnostopoulos, D. Weber, K. Rankin, K. Delasalle, and A. Raymond Thalidomide and dexamethasone for resistant multiple myeloma Br J Haematol 121 5 2003 768 771
102. J.-L. Harousseau, M.A. Dimopoulos, M. Wang, A. Corso, C. Chen, and M. Attal Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma Haematologica 95 10 2009 1738 1744
103. M. Dimopoulos, A. Spencer, M. Attal, H.M. Prince, J.-L. Harousseau, and A. Dmoszynska Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 21 2007 2123 2132
104. D.M. Weber, C. Chen, R. Niesvizky, M. Wang, A. Belch, and E.A. Stadtmauer Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 21 2007 2133 2142
105. M. Carrier, G. Le Gal, J. Tay, C. Wu, and A.Y. Lee Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis J Thromb Haemost 9 4 2011 653 663
106. B.A. Lwaleed, and A.J. Cooper Tissue factor expression and multidrug resistance in cancer: two aspects of a common cellular response to a hostile milieu Med Hypotheses 55 6 2000 470 473
107. M.E.W. Collier, C. Li, and C. Ettelaie Influence of Exogenous Tissue Factor on Estrogen Receptorα Expression in Breast Cancer Cells: Involvement of β1-Integrin, PAR2, and Mitogen-Activated Protein Kinase Activation Mol Cancer Res 6 12 2008 1807 1818
108. c; chimeric protein targeting tissue factor Clin Exp Metastasis 28 7 2011 689 700
109. T. Satoh, A. Oki, K. Uno, M. Sakurai, H. Ochi, and S. Okada High incidence of silent venous thromboembolism before treatment in ovarian cancer Br J Cancer 97 8 2007 1053 1057
110. K. Uno, S. Homma, T. Satoh, K. Nakanishi, D. Abe, and K. Matsumoto Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer Br J Cancer 96 2 2007 290 295
111. Y. Matsuura, G. Robertson, D.E. Marsden, S.-N. Kim, V. Gebski, and N.F. Hacker Thromboembolic complications in patients with clear cell carcinoma of the ovary Gynecol Oncol 104 2 2007 406 410
112. B.A. Goff, R. Sainz de la Cuesta, H.G. Muntz, D. Fleischhacker, M. Ek, and L.W. Rice Clear Cell Carcinoma of the Ovary: A Distinct Histologic Type with Poor Prognosis and Resistance to Platinum-Based Chemotherapy in Stage III Disease Gynecol Oncol 60 3 1996 412 417
113. L.R. Duska, L. Garrett, M. Henretta, J.S. Ferriss, L. Lee, and N. Horowitz When 'never-events' occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes Gynecol Oncol 116 3 2010 374 377
114. F.O. Recio, M.S. Piver, R.E. Hempling, and D.L. Driscoll Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy Cancer 78 10 1996 2157 2163
115. N. Yokota, S. Koizume, E. Miyagi, F. Hirahara, Y. Nakamura, and K. Kikuchi Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells Br J Cancer 101 12 2009 2023 2029
116. H. Itamochi, J. Kigawa, and N. Terakawa Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma Cancer Sci 99 4 2008 653 658
117. K. Shedden, X.T. Xie, P. Chandaroy, Y.T. Chang, and G.R. Rosania Expulsion of Small Molecules in Vesicles Shed by Cancer Cells Cancer Res 63 15 2003 4331 4337
118. R. Safaei, B.J. Larson, T.C. Cheng, M.A. Gibson, S. Otani, and W. Naerdemann Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells Mol Cancer Ther 4 10 2005 1595 1604
119. J.I. Zwicker Predictive value of tissue factor bearing microparticles in cancer associated thrombosis Thromb Res 125 Supplement 2(0) 2010 S89 S91